284 related articles for article (PubMed ID: 30528886)
21. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
Silva TA; Azevedo H
J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
[TBL] [Abstract][Full Text] [Related]
22. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
23. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
[TBL] [Abstract][Full Text] [Related]
24. Optimization of the different therapeutic strategies in muscle invasive bladder cancer using biomarkers.
Claps F; Mir C; Rubio-Briones J
Arch Esp Urol; 2022 Mar; 75(2):144-155. PubMed ID: 35332884
[TBL] [Abstract][Full Text] [Related]
25. Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives.
Gakis G
Eur Urol Focus; 2020 Jul; 6(4):632-638. PubMed ID: 31987763
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characterization of Bladder Cancer.
Chandrasekar T; Erlich A; Zlotta AR
Curr Urol Rep; 2018 Nov; 19(12):107. PubMed ID: 30390141
[TBL] [Abstract][Full Text] [Related]
27. Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review.
de Kruijff IE; Beije N; Martens JWM; de Wit R; Boormans JL; Sleijfer S
Eur Urol Oncol; 2021 Apr; 4(2):204-214. PubMed ID: 32059957
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
Boegemann M; Krabbe LM
Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
Jones RT; Felsenstein KM; Theodorescu D
Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
[TBL] [Abstract][Full Text] [Related]
30. Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Lotan Y; Woldu SL; Sanli O; Black P; Milowsky MI
BJU Int; 2018 Sep; 122(3):434-440. PubMed ID: 29603871
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
Koga F; Takemura K; Fukushima H
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223570
[TBL] [Abstract][Full Text] [Related]
32. Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.
Iacovino ML; Miceli CC; De Felice M; Barone B; Pompella L; Chiancone F; Di Zazzo E; Tirino G; Della Corte CM; Imbimbo C; De Vita F; Crocetto F
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163064
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
34. Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
Schardt J; Roth B; Seiler R
World J Urol; 2019 Sep; 37(9):1759-1765. PubMed ID: 30392011
[TBL] [Abstract][Full Text] [Related]
35. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.
Kiss B; Wyatt AW; Douglas J; Skuginna V; Mo F; Anderson S; Rotzer D; Fleischmann A; Genitsch V; Hayashi T; Neuenschwander M; Buerki C; Davicioni E; Collins C; Thalmann GN; Black PC; Seiler R
Sci Rep; 2017 Feb; 7():42713. PubMed ID: 28205537
[TBL] [Abstract][Full Text] [Related]
36. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
37. Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.
Lotan Y; de Jong JJ; Liu VYT; Bismar TA; Boorjian SA; Huang HC; Davicioni E; Mian OY; Wright JL; Necchi A; Dall'Era MA; Kaimakliotis HZ; Black PC; Gibb EA; Boormans JL
J Urol; 2022 Mar; 207(3):541-550. PubMed ID: 34643090
[TBL] [Abstract][Full Text] [Related]
38. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.
Kiselyov A; Bunimovich-Mendrazitsky S; Startsev V
Int J Cancer; 2016 Jun; 138(11):2562-9. PubMed ID: 26547270
[TBL] [Abstract][Full Text] [Related]
39. Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
Nössing C; Herek P; Shariat SF; Berger W; Englinger B
Curr Opin Urol; 2024 Jul; 34(4):251-257. PubMed ID: 38602053
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
